Skip to content

Viridian Therapeutics, Inc.\DE

VRDN

CIK 0001590750

← back to feed
Revenue (TTM)
$6.95M
−12.0% YoY Q1 May 2026
Net Income (TTM)
−$327.15M
−26.9% YoY Q1 May 2026
EPS Diluted (TTM)
−$4.05
−31.1% YoY Q1 May 2026
Gross Margin
65.0%
Q1 May 2026
Operating Margin
-5,133.3%
Q1 May 2026
Net Margin
-4,706.5%
Q1 May 2026
Free Cash Flow (TTM)
−$319.73M
Q1 May 2026
Cash
$24.86M
Q1 May 2026
Total Debt
$29.33M
Q1 May 2026
Shares Outstanding
103.07M sh
Q1 May 2026

Revenue & Net Income

EPS (Diluted)

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings